Kura Oncology to Report Second Quarter 2023 Financial Results
27 Julho 2023 - 8:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that it will report second quarter 2023 financial results after the
close of U.S. financial markets on Thursday, August 3, 2023. Kura’s
management will host a webcast and conference call at 4:30 p.m. ET
/ 1:30 p.m. PT that day to discuss the financial results and
provide a corporate update.
The live call may be accessed by dialing (888)
886-7786 for domestic callers and (416) 764-8658 for international
callers. A live webcast and archived replay of the event will be
available here or online from the investor relations section of the
company website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical
company committed to realizing the promise of precision medicines
for the treatment of cancer. Kura’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways.
Ziftomenib is a once-daily, oral drug candidate targeting the
menin-KMT2A protein-protein interaction for the treatment of
genetically defined acute myeloid leukemia (AML) patients with high
unmet need. Kura is currently enrolling patients in a Phase 2
registration-directed trial (KOMET-001) of ziftomenib in
NPM1-mutant relapsed or refractory AML. Kura is preparing to
initiate multiple Phase 1 trials to evaluate ziftomenib in
combination with current standards of care in earlier lines of
therapy and across multiple patient populations, including
NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and
selective farnesyl transferase inhibitor (FTI), is currently in a
Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for
patients with PIK3CA-dependent head and neck squamous cell
carcinoma. Kura intends to evaluate KO-2806, a next-generation FTI,
in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and
in combination with other targeted therapies in adult patients with
advanced solid tumors. For additional information, please visit
Kura’s website at www.kuraoncology.com.
Contacts
Investors:Pete De SpainExecutive Vice President,
Investor Relations &Corporate Communications(858)
500-8833pete@kuraoncology.com
Media:Alexandra WeingartenSenior Manager, Corporate
Communications(858) 500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Kura Oncology (NASDAQ:KURA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024